Feasibility of comparative health research outcome of novel surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study
Feasibility of comparative health research outcome of novel surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study
Background: Randomised controlled trials (RCTs) for surgical interventions have often proven difficult with calls for innovative approaches. The Imperial Prostate (IP4) Comparative Health Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS) study aims to deliver level 1 evidence on outcomes following focal therapy which involves treating just the tumour rather than whole-gland surgery or radiotherapy. Our aim is to test the feasibility of two parallel RCTs within an overarching strategy that fits with existing patient and physician equipoise and maximises the chances of success and potential benefit to patients and healthcare services. Methods and design: IP4-CHRONOS is a randomised, unblinded multi-centre study, including two parallel randomised controlled trials targeting the same patient population: IP4-CHRONOS-A and IP4-CHRONOS-B. IP4-CHRONOS-A is a 1:1 RCT and the other is a multi-arm, multi-stage (MAMS) RCT starting with three arms and a 1:1:1 randomisation. The two linked RCTs are discussed with patients at the time of consent and the choice of A or B is dependent on physician and patient equipoise. The primary outcome is the feasibility of recruitment, acceptance of randomisation and compliance to allocated arm. Results: This paper describes the statistical analysis plan (SAP) for the feasibility study within IP4-CHRONOS given its innovative approach. Version 1.0 of the SAP has been reviewed by the Trial Steering Committee (TSC), Chief Investigator (CI), Senior Statistician and Trial Statistician and signed off. The study is ongoing and recruiting. Recruitment is scheduled to finish later in 2021. The SAP documents approved methods and analyses that will be conducted. Since this is written in advance of the analysis, we avoid bias arising from prior knowledge of the study data and findings. Discussion: Our feasibility analysis will demonstrate if IP4-CHRONOS is feasible in terms of recruitment, randomisation and compliance, and whether to continue both A and B or just one to the main stage. Trial registration: ISRCTN ISRCTN17796995. Registered on 08 October 2019
Compliance, Feasibility, Focal therapy, Multi-centre multi-arm, Randomised controlled trial, Recruitment
Day, Emily
b1a9f30a-cda2-4f3b-9c56-c784922e7383
Prevost, A. Toby
5fd7066c-e170-46f6-8d3e-501532dc7810
Sydes, Matthew R.
6d7141c4-3171-43e8-b1e5-c93e6b7c7d3e
Reddy, Deepika
65700e0d-7c8d-4202-84bf-4e45eb1d4c56
Shah, Taimur T.
cb122d37-dd82-41a3-a65f-869fab4d0a95
Winkler, Mathias
771f8032-4868-4428-a44e-809ec3f525b6
Dudderidge, Tim
124ffc67-a11c-4428-9638-6d97576f9652
Staffurth, John
51734078-ea1f-4188-8d32-75f786921586
McCracken, Stuart
79a0b5bc-ae40-4b74-9996-bca0a5e683d1
Khoo, Vincent
d650b6bc-1490-439c-9ee1-e1e657b81d24
Jadav, Puja
d7d93f2b-7023-4c36-96f9-2e42ced4b1f9
Klimowska-Nassar, Natalia
3f43d195-d42a-4e7c-8c88-8c30879eb25f
Sasikaran, Thiagarajah
2b0e6f6b-915b-468f-833f-2e0159ac09b7
Ahmed, Hashim U.
3d2ebcef-5883-48f9-b343-a70992956332
Fiorentino, Francesca
e7bed6cb-dccf-437d-b58d-844bfc4e280a
18 August 2021
Day, Emily
b1a9f30a-cda2-4f3b-9c56-c784922e7383
Prevost, A. Toby
5fd7066c-e170-46f6-8d3e-501532dc7810
Sydes, Matthew R.
6d7141c4-3171-43e8-b1e5-c93e6b7c7d3e
Reddy, Deepika
65700e0d-7c8d-4202-84bf-4e45eb1d4c56
Shah, Taimur T.
cb122d37-dd82-41a3-a65f-869fab4d0a95
Winkler, Mathias
771f8032-4868-4428-a44e-809ec3f525b6
Dudderidge, Tim
124ffc67-a11c-4428-9638-6d97576f9652
Staffurth, John
51734078-ea1f-4188-8d32-75f786921586
McCracken, Stuart
79a0b5bc-ae40-4b74-9996-bca0a5e683d1
Khoo, Vincent
d650b6bc-1490-439c-9ee1-e1e657b81d24
Jadav, Puja
d7d93f2b-7023-4c36-96f9-2e42ced4b1f9
Klimowska-Nassar, Natalia
3f43d195-d42a-4e7c-8c88-8c30879eb25f
Sasikaran, Thiagarajah
2b0e6f6b-915b-468f-833f-2e0159ac09b7
Ahmed, Hashim U.
3d2ebcef-5883-48f9-b343-a70992956332
Fiorentino, Francesca
e7bed6cb-dccf-437d-b58d-844bfc4e280a
Day, Emily, Prevost, A. Toby, Sydes, Matthew R., Reddy, Deepika, Shah, Taimur T., Winkler, Mathias, Dudderidge, Tim, Staffurth, John, McCracken, Stuart, Khoo, Vincent, Jadav, Puja, Klimowska-Nassar, Natalia, Sasikaran, Thiagarajah, Ahmed, Hashim U. and Fiorentino, Francesca
(2021)
Feasibility of comparative health research outcome of novel surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study.
Trials, 22 (1), [547].
(doi:10.1186/s13063-021-05509-w).
Abstract
Background: Randomised controlled trials (RCTs) for surgical interventions have often proven difficult with calls for innovative approaches. The Imperial Prostate (IP4) Comparative Health Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS) study aims to deliver level 1 evidence on outcomes following focal therapy which involves treating just the tumour rather than whole-gland surgery or radiotherapy. Our aim is to test the feasibility of two parallel RCTs within an overarching strategy that fits with existing patient and physician equipoise and maximises the chances of success and potential benefit to patients and healthcare services. Methods and design: IP4-CHRONOS is a randomised, unblinded multi-centre study, including two parallel randomised controlled trials targeting the same patient population: IP4-CHRONOS-A and IP4-CHRONOS-B. IP4-CHRONOS-A is a 1:1 RCT and the other is a multi-arm, multi-stage (MAMS) RCT starting with three arms and a 1:1:1 randomisation. The two linked RCTs are discussed with patients at the time of consent and the choice of A or B is dependent on physician and patient equipoise. The primary outcome is the feasibility of recruitment, acceptance of randomisation and compliance to allocated arm. Results: This paper describes the statistical analysis plan (SAP) for the feasibility study within IP4-CHRONOS given its innovative approach. Version 1.0 of the SAP has been reviewed by the Trial Steering Committee (TSC), Chief Investigator (CI), Senior Statistician and Trial Statistician and signed off. The study is ongoing and recruiting. Recruitment is scheduled to finish later in 2021. The SAP documents approved methods and analyses that will be conducted. Since this is written in advance of the analysis, we avoid bias arising from prior knowledge of the study data and findings. Discussion: Our feasibility analysis will demonstrate if IP4-CHRONOS is feasible in terms of recruitment, randomisation and compliance, and whether to continue both A and B or just one to the main stage. Trial registration: ISRCTN ISRCTN17796995. Registered on 08 October 2019
Text
s13063-021-05509-w
- Version of Record
More information
Published date: 18 August 2021
Additional Information:
Funding Information:
TTS receives funding from Prostate Cancer UK and the St Peters Trust for clinical research and has received funding for conference attendance from Astellas, Ferring and Galil Medical.
Funding Information:
HA’s research is supported by core funding from the United Kingdom’s National Institute of Health Research (NIHR) Imperial Biomedical Research Centre. HA currently receives funding from the Wellcome Trust, Medical Research Council (UK), Cancer Research UK, Prostate Cancer UK, The Urology Foundation, BMA Foundation, Imperial Health Charity, NIHR Imperial BRC, Sonacare Inc., Trod Medical and Sophiris Biocorp for trials in prostate cancer. HA is a paid medical consultant for Sophiris Biocorp and Sonacare Inc. HA is a proctor for cryotherapy and HIFU and paid for training other surgeons in these procedures. HA is paid proctor for Rezum for the treatment of benign prostate hyperplasia.
Funding Information:
MRS reports grants and non-financial support outside the submitted work from Astellas, grants from Clovis Oncology, grants and non-financial support from Janssen, grants and non-financial support from Novartis, grants and non-financial support from Pfizer, grants and non-financial support from Sanofi and personal fees from Lilly Oncology and personal fees from Janssen all outside the submitted work.
Funding Information:
IP4-CHRONOS pilot is funded by Prostate Cancer UK (Award number RIA17-ST2-012).
Keywords:
Compliance, Feasibility, Focal therapy, Multi-centre multi-arm, Randomised controlled trial, Recruitment
Identifiers
Local EPrints ID: 455681
URI: http://eprints.soton.ac.uk/id/eprint/455681
ISSN: 1745-6215
PURE UUID: 1fc09ecd-30cd-4547-b56b-64d773deafb4
Catalogue record
Date deposited: 30 Mar 2022 16:49
Last modified: 17 Mar 2024 12:58
Export record
Altmetrics
Contributors
Author:
Emily Day
Author:
A. Toby Prevost
Author:
Matthew R. Sydes
Author:
Deepika Reddy
Author:
Taimur T. Shah
Author:
Mathias Winkler
Author:
Tim Dudderidge
Author:
John Staffurth
Author:
Stuart McCracken
Author:
Vincent Khoo
Author:
Puja Jadav
Author:
Natalia Klimowska-Nassar
Author:
Thiagarajah Sasikaran
Author:
Hashim U. Ahmed
Author:
Francesca Fiorentino
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics